Accretion Pharmaceuticals P/B Ratio
Current P/B Ratio
2.55
Moderate Valuation
High - Premium to book value, growth expectations or asset-light model
Accretion Pharmaceuticals (ACCPL) P/B ratio is 2.55 (Moderate), book value per share ₹18.75 vs Healthcare average P/B of -1.0 — High - Premium to book value, growth expectations or asset-light model. For live price, earnings yield and the full fundamental profile, see ACCPL stock overview.
Current Valuation Metrics
P/B Ratio
2.55
Current Price
₹
Book Value/Share
₹18.75
Exchange
None
Book Value Breakdown (2025)
Balance Sheet Components
Total Equity
₹15 Cr
Share Capital
₹8 Cr
Reserves & Surplus
₹7 Cr
Outstanding Shares
8,000,000
Book Value per Share
₹18.75
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-1.0
Sector Median
0.62
Sector Rank
#11 of 50
Sector Percentile
22.0%
ACCPL P/B Ratio — Valuation Insights & Book Value Analysis
Accretion Pharmaceuticals price-to-book ratio interpretation, valuation status and historical context — current P/B 2.55 (Moderate).
- Trading at premium to sector average PB of -1.0
ACCPL vs Healthcare Peers — P/B Ratio Comparison
Accretion Pharmaceuticals P/B 2.55 vs Healthcare average -1.0, median 0.62 — range -36.63–1.05.
Sector Average
-1.0
Sector Median
0.62
Lowest P/B
-36.63
Highest P/B
1.05
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -36.63 | ₹28 | Low |
| Sun Pharma Advanced Rese… | SPARC | -13.83 | ₹4,744 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.35 | ₹76 | Low |
| Parmax Pharma | PARMAX | -2.09 | ₹12 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.8 | ₹128 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |